- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01799733
Alternative Treatments for Premenstrual Dysphoric Disorder
January 20, 2022 updated by: Barbara L. Parry, M.D., University of California, San Diego
The primary aim of this study is to examine the effects of co-administered wake therapy followed by light treatment on mood, and secondarily on circadian rhythms, to test the hypothesis that critically-timed chronotherapy improves mood by correcting phase disturbances in melatonin and sleep in women with Premenstrual Dysphoric Disorder.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The design is a randomized cross-over contrasting Late Wake Therapy plus morning bright light (LWT+Am BWL)vs.
Early Wake Therapy plus evening bright light (EWT+PM BWL)administered in the luteal phase of two separate menstrual cycles, and preceded by 2 evaluation months.
To lessen the patient's burden, the 1-night EWT or LWT and the following 7-day BWL interventions will be conducted at home, given at a fixed point in each menstrual cycle, from day 1 to 7 after the mid-cycle luteinizing hormone(LH) surge (ovulation).
We anticipate that LWT+7 days of AM BWL (vs.
EWT+PM BWL) will produce much greater mood benefits and larger physiological responses, than the one-time light pulses used in our earlier phase-shift studies.
Study Type
Interventional
Enrollment (Actual)
43
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92103
- UCSD Medical Center, Hillcrest
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Age: 18-45 years.
- Women with regular ovulatory menstrual cycles 26-32 days in length (for at least the previous six months).
- A history of a depressive (but not bipolar) mood disorder, but not an ongoing episode (symptom free for the last 12 months).
- Patients must meet DSM-IV criteria for Premenstrual Dysphoric Disorder (that includes irritability).
- Objective ratings: mean HRSD < 7 for follicular phase (day 5-10 of cycle after menses); mean HRSD > 14 for premenstrual (luteal) phase (6 days prior to onset of menses onward).
- Subjective ratings: mean Beck Depression Inventory < 5 follicular phase; > 10 premenstrual (luteal) phase, or
- Daily ratings: minimal symptoms (mean less than 50 on 100mm scale) follicular phase; at least a 30% increase in mean affective symptom ratings, premenstrual (luteal) phase.
- By clinical assessment and ratings, the patient has reported a history (for at least the last six months) of recurrent, moderate to severe premenstrual mood symptoms that impair some aspect of social or occupational functioning and that remit within a few days after the onset of menses. This pattern is prospectively documented with subjective and objective ratings over a 2-3 month interval. Patients must demonstrate a consistency of symptoms and a long enough duration of symptoms (7-10 days) to allow for study.
- Subjects willing to endure the rigors of a long-term (up to 6 months) research study.
Exclusion Criteria:
- Subjects with significant medical illness including hepatic (abnormal liver function tests), neurological, renal, cardiac, pulmonary, hematologic, gastrointestinal, or metabolic disorders.
- Subjects who are lactating, are within 6 months postpartum, or have an irregular sleep- wake cycle, e.g., from having very young children in the home.
- Subjects who are using hormonal contraception (within six months prior to the study).
- Subjects using other medication within one month of initiating the study or anytime during the study.
- Subjects with significant psychiatric disorder (schizophrenia, bipolar disorder, anxiety disorders, eating disorders, personality disorders, sleep disorders). An ongoing major depressive episode within the last year is reason for exclusion, although a previous history of a depressive episode is not (using DSM-IV diagnostic criteria for a major depressive episode).
- Subjects with a recent history (within the past year) of drug or alcohol abuse.
- Subjects with clinically significant abnormal laboratory values.
- Subjects with irregular menstrual cycles (cycle lengths vary greater than 3 days).
- Subjects unlikely to cooperate with the requirements of the study.
- Subjects needing frequent or continuous use of any medication, including nicotine (> 5 cigarettes daily).
- Subjects whose prospective ratings do not show cyclic variation in association with the menstrual cycle (as per inclusion criteria).
- Subjects with an irregular sleep schedule, extreme chronotypes or a sleep-wake cycle that does not correspond to the environmental light-dark cycle (e.g., subjects within 2 weeks of transmeridian travel, night shift workers, or those with significant advanced or delayed sleep phase syndromes). To enhance precision of the timing of the light stimulus on circadian phase (temporal resolution), we will exclude women with habitual sleep onset times after midnight or wake times after 9 am.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: LWT+AM BWL
Late-wake therapy in combination with morning bright white light
|
One night of late wake therapy (LWT)(sleep 21:00-01:00 h, followed by wakefulness) plus 7 days of morning bright white light (AM BWL)(light-emitting diode-LED administered for 60 minutes, starting within 30 minutes of habitual wake time)
|
Placebo Comparator: EWT+PM BWL
Early-wake therapy in combination with evening bright white light
|
One night of early wake therapy (EWT) (wakefulness until 03:00 h, then sleep 03:00-07:00 h) plus 7 nights of evening bright white light (PM BWL)(light-emitting diode-LED administered 90 minutes before habitual sleep onset, for 60 minutes)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-Related Changes from baseline in mood ratings
Time Frame: baseline (month 2) and 1-2 days post intervention (months 3,5)
|
Mood ratings include Hamilton Rating Scale for Depression (HRSD), Beck Depression Inventory (BDI), atypical depression symptoms as part of the Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorders version (SIGH-SAD), Beck Anxiety Inventory (BAI), mania ratings, the Psychological General Well-Being Index (PGWI) and daily mood self-ratings (DMR) that include core PMDD symptoms of anxiety and irritability as required during diagnostic evaluation, before, during and after each wake and light intervention at the same time of day (between 15:00-17:00 h).
To assess more acute effects on mood that may occur more rapidly during the wake interventions, subjects will complete DMRs twice daily beginning the evening before the wake therapy intervention and continuing until the morning after the recovery night of sleep.
|
baseline (month 2) and 1-2 days post intervention (months 3,5)
|
Treatment-Related Changes from Baseline in Urinary 6-sulfatoxymelatonin (6-SMT)
Time Frame: baseline (month 2) and 1-2 days post intervention (months 3,5)
|
6-SMT is a principal melatonin metabolite that is abundant in urine, well correlated with plasma melatonin, and serves as an excellent marker for circadian phase response.
|
baseline (month 2) and 1-2 days post intervention (months 3,5)
|
Treatment-related changes in objective and subjective sleep measures
Time Frame: baseline (month 2) and 1-2 days post intervention (months 3,5)
|
Using actigraphy, we will obtain objective measures of the sleep/wake cycle to ensure appropriate sleep/wake times during wake therapy, and during the light interventions as it is an important biological rhythm with which to compare the intervention-induced melatonin rhythm changes.
To assess subjective sleep quality, we will use the Pittsburgh Sleep Quality Index (PSQI) and a visual analogue scale.
|
baseline (month 2) and 1-2 days post intervention (months 3,5)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effects of expectation, morningness/eveningness and seasonality on primary outcome measures
Time Frame: baseline
|
Prior to entering the study, subjects will complete expectation forms measuring their expectation for change with the interventions (100 mm line from "much worse" to "much better") as well as Horne-Östberg scales to assess morningness and eveningness, as these variables may mediate or moderate primary outcome measures.
To determine whether seasonality affects outcome, subjects will complete the Seasonal Pattern Assessment Questionnaire (SPAQ).
|
baseline
|
Treatment-related changes from baseline in reproductive hormones
Time Frame: baseline (month 2) and 1-2 days post intervention (months 3,5)
|
We will obtain overnight urinary samples for estradiol, progesterone, gonadotropins and prolactin (obtained at the same time of 6-SMT overnight collections in baseline and intervention months).
|
baseline (month 2) and 1-2 days post intervention (months 3,5)
|
Subjective visual analog scale-based global assessment of treatment effectiveness
Time Frame: 1-2 days post second intervention (month 5)
|
Following both treatment interventions, subjects will complete a visual analog scale-based global assessment of treatment effectiveness.
|
1-2 days post second intervention (month 5)
|
Subjective assessment of side effects to treatment
Time Frame: 1-2 days post intervention (months 3,5)
|
Following each treatment interventions, subjects will complete an assessment of side effects using the Side Effects Checklist.
|
1-2 days post intervention (months 3,5)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Barbara L Parry, M.D., University of California, San Diego
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 18, 2013
Primary Completion (Actual)
May 10, 2018
Study Completion (Actual)
July 3, 2018
Study Registration Dates
First Submitted
February 25, 2013
First Submitted That Met QC Criteria
February 25, 2013
First Posted (Estimate)
February 27, 2013
Study Record Updates
Last Update Posted (Actual)
February 4, 2022
Last Update Submitted That Met QC Criteria
January 20, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R01AT007169-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premenstrual Dysphoric Disorder
-
Tel-Aviv Sourasky Medical CenterUnknownDepression | Premenstrual Dysphoric Disorder (PMDD)Israel
-
BayerCompleted
-
Asarina PharmaErgomedCompletedPremenstrual Dysphoric DisorderSweden, Germany, Poland, United Kingdom
-
University of North Carolina, Chapel HillFoundation of Hope, North CarolinaTerminatedPremenstrual Dysphoric Disorder
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedPremenstrual Dysphoric DisorderUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownPremenstrual Dysphoric Disorder
-
University of North Carolina, Chapel HillCompletedPremenstrual Dysphoric DisorderUnited States
-
University of Illinois at ChicagoCompletedPremenstrual Dysphoric DisorderUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)CompletedPremenstrual Dysphoric DisorderUnited States
-
Umecrine Mood ABCompletedPremenstrual Dysphoric DisorderSweden
Clinical Trials on LWT+AM BWL
-
University of PennsylvaniaNational Institute of Nursing Research (NINR)Recruiting
-
Virginia Commonwealth UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of California, San DiegoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsActive, not recruitingOverweight and ObesityUnited States
-
Virginia Commonwealth UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Bowling Green State UniversityUnknownOverweight and Obesity | Emotional Eating
-
Istanbul University - Cerrahpasa (IUC)Not yet recruitingSleep Quality | Mother-Infant Interaction | AttachmentTurkey
-
University of California, San DiegoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedObesity | OverweightUnited States
-
University of PennsylvaniaWeight Watchers InternationalCompletedObesity | Weight Loss | StigmatizationUnited States
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruitingHealthy | Overweight and ObesityUnited States
-
Yale UniversityCompletedWeight Loss | Overweight and Obesity | Food AddictionUnited States